Anika Therapeutics 2025 Q3 Earnings Narrows Net Loss by 92.2%

Anika Therapeutics (ANIK) reported fiscal 2025 Q3 earnings on Nov 5, 2025, . The company narrowly beat revenue estimates and maintained full-year guidance, , marking a 122.22% beat.

Revenue

, while the Commercial Channel contributed $11.97 million, bringing the total to $27.82 million. , .

Earnings/Net Income

. The net loss reduced to $-2.33 million, . This marks a significant step toward profitability, though challenges persist in operational costs and R&D expenses.

Post-Earnings Price Action Review

.

CEO Commentary

The CEO emphasized navigating supply chain constraints and competitive pressures while investing in R&D for orthopedic and spine therapies. Regulatory progress and partnerships are expected to drive long-term growth, alongside cost discipline to mitigate near-term financial pressures.

Guidance

, . .

Additional News

Anika filed the final PMA module for Hyalofast with the FDA, including 24-month FastTRACK trial data and real-world evidence. , signaling confidence in its financial stability. .

Key Financial Highlights

• Revenue.

• Non-GAAP EPS.

• Net Loss.

• Full-Year Guidance,

Strategic Updates

• Hyalofast PMA Filing.

• Share Buyback.

• R&D Focus.

Market Outlook

, . , .